Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Suzhou City, China Clinical Trials

A listing of Suzhou City, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (97) clinical trials

Bioseal Dural Sealing Study BIOS-14-001

This is a randomized, single blinded, multi-center controlled study evaluating the effectiveness of Bioseal as an adjunct to sutured dural closure compared to control to obtain an intra-operative watertight dural closure.

Phase

3.13 miles

Learn More »

A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

This is a Phase III/IV, single-arm, multicenter study of the long-term safety and efficacy of atezolizumab treatment in participants with Stage IIIb or Stage IV NSCLC who have progressed after standard systemic chemotherapy (including if given in combination with anti-programmed cell death protein 1 [anti-PD-1] therapy, after anti-PD-1 as monotherapy, ...

Phase

3.13 miles

Learn More »

Autologous Bronchial Basal Cells Transplantation for Treatment of CRD Including COPD BE and PF

Chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), bronchiectasis (BE) or pulmonary fibrosis (PF) are usually not curable with damaged pulmonary structure and function. Bronchial basal cells are proved to regenerate bronchus and alveoli to repair the pulmonary injuries. In this study, we intend to perform an open, single-armed ...

Phase N/A

3.13 miles

Learn More »

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

This is an open label, single-arm, multicenter phase 3 study to evaluate efficacy and safety of the BiTE (bispecific T cell engager) antibody blinatumomab in Chinese adult subjects with relapsed/refractory B-precursor ALL. The study will consist of a screening period, a treatment period, and a follow-up period. Treatment will consist ...

Phase

3.13 miles

Learn More »

Study of Efficacy and Safety of Xolair (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria

A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of Xolair (omalizumab) in Chinese patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamine treatment The purpose of the study is to evaluate the efficacy of Xolair compared with placebo in patients with refractory ...

Phase

3.13 miles

Learn More »

Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)

The purpose of this study is to compare the clinical efficacy and safety of IAC regimen and IA regimen as induction chemotherapy for initial diagnosed AML patients. 840 cases are supposed to recruited in 3 years.

Phase

3.13 miles

Learn More »

Haplo-SCT vs ASCT With or Without Decitabine in AML CR1

A multicentre, prospective, open-label clinical study, including a randomized controlled study in low or intermediate-risk group patients, and a cohort study of maintenance treatment with decitabine after ASCT.

Phase

3.13 miles

Learn More »

Functional Neural Regeneration Collagen Scaffold Transplantation in Acute Spinal Cord Injury Patients

The study is designed to assess the safety and efficacy of functional neural regeneration collagen scaffold transplanted into acute spinal cord injury patients.

Phase

3.13 miles

Learn More »

PDD vs PAD to Treat Initially Diagnosed MM

The purpose of this study is to determine whether doxorubicin hydrochloride liposome is superior to doxorubicin when combined with bortizomib and dexamethasone for treating patient with initially diagnosed multiple myeloma.

Phase

3.13 miles

Learn More »

Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma

Primary Outcome Measures: Area under the curve (AUC) forTQB2303 and rituximab concentrations [ Time Frame: 85 days ] Secondary Outcome Measures: The Maximum Concentration (Cmax) of the TQB2303 and rituximab [ Time Frame: 85 days ] The area under the plasma concentration-time curve from 0 to inf (infinite) time (AUC0-); ...

Phase

3.13 miles

Learn More »